These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

564 related items for PubMed ID: 31462566

  • 1. A Membrane-Anchored Short-Peptide Fusion Inhibitor Fully Protects Target Cells from Infections of Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
    Tang X, Jin H, Chen Y, Li L, Zhu Y, Chong H, He Y.
    J Virol; 2019 Nov 15; 93(22):. PubMed ID: 31462566
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Design and Characterization of Cholesterylated Peptide HIV-1/2 Fusion Inhibitors with Extremely Potent and Long-Lasting Antiviral Activity.
    Zhu Y, Chong H, Yu D, Guo Y, Zhou Y, He Y.
    J Virol; 2019 Jun 01; 93(11):. PubMed ID: 30867304
    [Abstract] [Full Text] [Related]

  • 8. Glycosylphosphatidylinositol-Anchored Anti-HIV scFv Efficiently Protects CD4 T Cells from HIV-1 Infection and Deletion in hu-PBL Mice.
    Ye C, Wang W, Cheng L, Li G, Wen M, Wang Q, Zhang Q, Li D, Zhou P, Su L.
    J Virol; 2017 Feb 01; 91(3):. PubMed ID: 27881659
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Design of a Bispecific HIV Entry Inhibitor Targeting the Cell Receptor CD4 and Viral Fusion Protein Gp41.
    Yan H, Wu T, Chen Y, Jin H, Li L, Zhu Y, Chong H, He Y.
    Front Cell Infect Microbiol; 2022 Feb 01; 12():916487. PubMed ID: 35711654
    [Abstract] [Full Text] [Related]

  • 13. Potent and Broad Inhibition of HIV-1 by a Peptide from the gp41 Heptad Repeat-2 Domain Conjugated to the CXCR4 Amino Terminus.
    Leslie GJ, Wang J, Richardson MW, Haggarty BS, Hua KL, Duong J, Secreto AJ, Jordon AP, Romano J, Kumar KE, DeClercq JJ, Gregory PD, June CH, Root MJ, Riley JL, Holmes MC, Hoxie JA.
    PLoS Pathog; 2016 Nov 01; 12(11):e1005983. PubMed ID: 27855210
    [Abstract] [Full Text] [Related]

  • 14. Molecular mechanism of HIV-1 resistance to sifuvirtide, a clinical trial-approved membrane fusion inhibitor.
    Yu D, Ding X, Liu Z, Wu X, Zhu Y, Wei H, Chong H, Cui S, He Y.
    J Biol Chem; 2018 Aug 17; 293(33):12703-12718. PubMed ID: 29929981
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Reduced Susceptibility to VIRIP-Based HIV-1 Entry Inhibitors Has a High Genetic Barrier and Severe Fitness Costs.
    Müller JA, Glöckle A, Gawanbacht A, Geyer M, Münch J, Kirchhoff F.
    J Virol; 2018 Sep 01; 92(17):. PubMed ID: 29925662
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A low-molecular-weight entry inhibitor of both CCR5- and CXCR4-tropic strains of human immunodeficiency virus type 1 targets a novel site on gp41.
    Murray EJ, Leaman DP, Pawa N, Perkins H, Pickford C, Perros M, Zwick MB, Butler SL.
    J Virol; 2010 Jul 01; 84(14):7288-99. PubMed ID: 20427524
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.